

**NUMIRA BIOSCIENCES ANNOUNCES PARTICIPATION ON “UTAH’S GOVERNOR’S OFFICE
OF ECONOMIC DEVELOPMENT – FALL TECHNOLOGY COMMERCIALIZATION
AND INNOVATION PROGRAM” (TCIP) GRANT REVIEW BOARD**

Sergio Vasquez named to the State’s Grant Review Board

SALT LAKE CITY, Utah, January 10, 2012 – Numira Biosciences, a specialty contract research organization and leader in high resolution, 3D imaging services and visualization software for the life science market, today announced that Sergio X. Vasquez, Application Development Scientist and Manager of Laboratory Operations at Numira, joined the Review Board as a Life Sciences Expert for the Fall Technology Commercialization and Innovation Program grant review session. The meeting was held September 29th, 2011, at the Utah State Capital, in Salt Lake City, Utah.

Three times each year, companies that are developing and commercializing technologies from Utah’s colleges and universities are eligible to apply and present in a one-day event to secure grant funding from the State. Industry experts volunteer a day to review and select the best projects for grant funding. Mr. Vasquez has been named to the Review Board.

Mr. Vasquez is a recognized expert in the field of small-animal imaging and preclinical genetic models. He received his honors degree from the University of Oklahoma in Zoology (summa cum laude), specializing in developmental biology and performing basic research on embryonic zebrafish models of circadian rhythmicity at the Stephenson Research and Technology Center in Norman, Oklahoma.

Mr. Vasquez began translational therapeutic research in 2005 at the Greehey Children’s Cancer Research Institute (GCCRI), at the University of Texas Health Science Center (UTHSCSA), in San Antonio, Texas. While performing validation and characterization studies on conditional genetic murine models of human alveolar and embryonal rhabdomyosarcoma, his focus included optimization of small animal microCT imaging for skeletal and soft tissue image capture.

In addition to publishing novel imaging strategies for *ex-vivo* skeletal, soft tissue and vascular studies, he co-authored several patented methods for imaging in-situ atherosclerotic plaques and cartilage in preclinical animal specimens.

The purpose of the Technology Commercialization & Innovation Program (TCIP), a State funded GRANT program, is to accelerate the commercialization of promising technologies that have strategic value for Utah. The end goal is to help drive economic development and job creation.

About Numira Biosciences

Numira is a rapidly growing provider of specialty contract research services to the pharmaceutical and medical device industries. Through the combination of several novel technologies and capabilities, we provide clients with an unmatched array of pre-clinical services for their research programs in inflammation, cardiovascular, oncology, pulmonary, renal, bone, and other areas of disease and/or therapy. Moreover, we are a recognized leader in high-resolution, quantitative imaging for drug and device development. Numira, a privately-held company, is venture-backed by vSpring Capital, the Tech

Coast Angels, and Crocker Ventures. For more information on Numira, please visit www.numirabio.com.

Contact Info:

Mary Mathis

Senior Director, Marketing & Communications

Numira Biosciences Inc.

Tel: (801) 320-0682 Ext 325

mmathis@numirabio.com